Lung cancer remains a leading cause of cancer death globally, with a significant rise in cases among non-smokers attributed ...

Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) ...

A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual ...

A recent study published in The Lancet Respiratory Medicine revealed an increase in lung cancer cases among non-smokers, ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

Mayo Clinic researchers have pioneered an artificial intelligence (AI) tool, called OmicsFootPrint, that helps convert vast amounts of complex biological data into two-dimensional circular images.

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...

February 4, 2025, marks World Cancer Day, a global initiative to raise awareness about the impact of cancer, encourage early detection, and support advancements in treatment. Cancer is a battle that ...

Q4 2024 Earnings Conference Call February 4, 2025 10:30 AM ETCompany ParticipantsFrancesca DeMartino - Senior Vice President, ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...